High Dear Sirs,
In vivo studies on germ cells . 
Introduction
Aspartame is a methyl ester of a dipeptide composed of aspartic acid and phenylalanine. The chemical structure is shown in Fig. 1 .
There are two forms of aspartame, an a and a b form, but only the a form is sweet. It is approximately 200 times sweeter than sucrose. It is approved for use in a wide range of food products in more than 90 countries around the world and is estimated to have been added to over 6000 different products (Butchko and Stargel, 2001) .
Aspartame has been extensively evaluated for genotoxic effects in microbial, cell culture and animal models. It has also been subject to a number of carcinogenicity studies. The carcinogenicity of aspartame was reviewed in detail by Magnuson et al. (2007) , and more briefly by Yilmaz and Uçar (2014) , and has been the subject of a number of regulatory opinions (SCF, 2002; EFSA, 2006 EFSA, , 2009a EFSA, , 2009b EFSA, , 2011a EFSA, , 2013 . However, the genotoxicity of aspartame was only briefly reviewed by both Magnuson et al. (2007) and by Yilmaz and Uçar (2014) . The latter authors concluded that aspartame was a moderate genotoxic agent, whereas Magnuson et al. (2007) concluded that extensive in vitro and in vivo studies provide ample evidence that aspartame is not genotoxic. The purpose of this manuscript is therefore to describe in more detail and to critically review all the available genotoxicity data on aspartame.
In vitro studies
A number of in vitro genotoxicity studies, including bacterial, chromosomal aberration, micronucleus and DNA repair tests, have been performed on aspartame. The studies and their findings are summarised in Table 1 . Brief additional comments on the significance of the findings are given below.
Bacterial mutagenicity
The available Ames tests with aspartame are summarised in Table 1 . It can be concluded from the combined results of these four studies that aspartame is not a mutagen for bacterial cells. It is noted that none of the studies fully comply with current regulatory guidelines in that a bacterial test strain for the detection of Increases in the occurrence of haploid mitotic segregants and mitotic recombination at concs.
of 800 and 1000 mg/mL Gebara et al. (2003) mutagens acting specifically on AT base-pairs (i.e. Salmonella typhimurium TA102 or E. coli WP2 uvrA) was not included (Gatehouse et al., 1994; ICH, 1995 ICH, , 2011 OECD, 1997) . Therefore, the possibility of induction of oxidative or cross-linking damage in these tests cannot be excluded. However, these modes of action will have been addressed in the mammalian cell tests discussed below. In addition to standard bacterial mutagenicity assays (Ames tests), the possible formation of bacterial mutagens as a result of the potential nitrosation of aspartame has also been investigated (Shephard et al., 1991; 1993) . In these studies aspartame (over a concentration range of 5e30 mM) was reacted with sodium nitrite (40 mM) at pH 3.5 for 30 min at 37 C. The reaction was then terminated by addition of ammonium sulphamate (to remove nonreacted nitrite), and then aliquots of the reaction mixture were evaluated for mutagenic activity. In this assay four strains of S. typhimurium were used (TA100, TA98, TA102 and TA104) in a preincubation procedure (30 min/37 C). It was found that nitrosation of aspartame resulted in the formation of nitroso-species with mutagenic activity towards TA100, TA104 and TA98. No significant effects were obtained with strain TA102. The most sensitive strain was TA100, although the effects were reduced in the presence of liver S9 fraction. The authors concluded that the mutagenic products resulted from the nitrosation of the primary amine group, and not the amide bond, within aspartame. The no-effect level (in terms of nitrite concentration within the reaction mixture) was between 8 and 12 mM for this strain. It should be noted that the nitrite concentration within the normal human fasting acidic stomach is approximately 1e5 mM (Schlag et al., 1980) , whilst gastric hypochlorhydria results in an increase in these levels to 40 mM (Ruddel et al., 1976) . Therefore the formation of detectable levels of mutagenic species in these experiments with aspartame was only manifest at nitrite concentrations that were more than 200e1600efold higher than the levels normally pertaining in humans in vivo. Furthermore the authors calculated that after extrapolation from the mM concentrations of reactants used in their experiments to the mM concentrations present within the stomach, the amine nitrosation yields would drop by a factor of a million-fold. Consequently it can be concluded that the nitrosation products of aspartame would not contribute significantly to the endogenous burden of nitrosation products which result from other dietary sources.
A metabolite of aspartame, phenylalanine has also been tested for mutagenicity using E. coli K12 uvrB (Sargentini and Smith, 1986) . In this study the mutational end-point involved reversion of the lacZ 53 gene to Lac þ and mutagenesis was measured using an agar plate assay. A small increase in reversion frequency (up to approximately 1.6-fold) was obtained after exposure to phenylalanine at concentrations between 0.5 and 2 mM. No significant effects were obtained with the wild-type (excision repair proficient) strain indicating that excisable mutagenic lesions were involved. The small increase in base-substitution mutations reported in this study contrast with the uniformly negative results reported for the parent compound aspartame in S. typhimurium strains TA100 and TA1535, which also detect base-substitution mutations and which are also excision repair deficient due to a deletion in the uvrB gene. Consequently the biological relevance of these data with a bacterial strain that is not routinely used for regulatory testing is questionable.
Chromosomal aberrations (CA) in mammalian cells
The single study in which induction of CA was investigated (Rencuzogullari et al., 2004 ) is summarised in Table 1 . Statistically significant increases in CA frequency were obtained at all three test concentrations after both treatment regimens, and there was a dose-relationship for the 24 h treatments. At the highest test concentration the increases reached 4Â and 3.5Â control levels (24 and 48 h treatments respectively). The increased CA frequencies were not due to changes in pH or osmolality of the treatment medium. Based on the levels of mitotic inhibition achieved, which were not excessive, it would seem unlikely that the increased CA were an indirect consequence of high levels of cytotoxicity. However, EFSA (2013) considered that the pattern of results obtained did suggest an indirect clastogenic effect which was secondary to cytotoxicity, and not related to primary DNA damage. This was based mainly on the failure of aspartame to induce sister-chromatid exchanges and the absence of any DNA-reactive electrophilic centres. We agree with these comments. The failure to include exogenous metabolic activation in this study may be important. Aspartame is hydrolysed to a number of products including methanol, which can be further metabolised to formaldehyde, which is a DNA cross-linking agent, known to induce chromosome damage in mammalian cells (Schmid et al., 1986) . Whilst the oxidation of methanol to formaldehyde in the absence of S9 is unlikely, the clastogenic potential of aspartame in the presence of S9 has not been evaluated in this study.
In vitro micronucleus (MN) tests
The single study in which induction of MN was investigated, by the same group that studied CA induction (Rencuzogullari et al., 2004) , is summarised in Table 1 . Although a small, but statistically significant increase in MN frequency was obtained at the highest test concentration of 2000 mg/mL for both treatment regimens, the study design (in particular treatment times and measure of cytotoxicity) was unusual. Some toxicity was induced, and the ratio of binucleate to mononucleate cells fell by >50% at all 3 concentrations scored after 48 h treatment. Again, we agree with EFSA (2013) , that the pattern of results obtained suggests an indirect clastogenic effect which was secondary to cytotoxicity, and not related to primary DNA damage. The failure to include treatments in the presence of exogenous metabolic activation may again be important.
In vitro effects on DNA repair
The single study on induction of unscheduled DNA synthesis (UDS) in rat hepatocytes (Jeffrey and Williams, 2000) is summarised in Table 1 . The result was negative at concentrations up to 10 mM.
Other in vitro studies
A mitotic recombination test in yeast (Gebara et al., 2003) is summarised in Table 1 . Whilst positive responses were seen, the biological relevance of these changes in terms of the detection of potential genotoxic carcinogens is not known, and this is reflected by the absence of such assay types from any regulatory guidelines for genotoxicity testing.
Summary of in vitro results
Based upon the results obtained in four independent bacterial mutagenicity studies (Ames tests) performed over a 30 year period, it can be concluded that aspartame is not a mutagen for bacterial cells. These studies are not fully compliant with current guidelines, in that they lacked the inclusion of a bacterial test strain to detect mutagens acting specifically on AT base-pairs. However, such activity would be detected in mammalian cell tests for chromosome damage.
The small increase in MN induction and the increased frequencies of cells with CA after the in vitro exposure of human lymphocytes to aspartame are considered to be secondary to cytotoxicity and not indicative of DNA damage. However, the failure to include treatments in the presence of exogenous metabolic activation merits discussion. Aspartame can be hydrolysed to produce four metabolites: aspartic acid, phenylalanine, methanol and a cyclised diketopiperazine. The latter compound is also produced as a breakdown product at temperatures above 30 C. Methanol can be further metabolised to formaldehyde, which is a DNA crosslinking agent, known to induce chromosome damage in mammalian cells (Schmid et al., 1986) . However, there is no evidence that methanol is clastogenic in vitro (see EFSA, 2013) , and so its conversion to formaldehyde in cultured cells may not be efficient. Since the oxidising capabilities of human lymphocytes in the absence of S9 are expected to be poor, it is unlikely that the clastogenic effects observed in human lymphocytes after exposure in vitro to high concentrations of aspartame are due to the intracellular formation of small amounts of formaldehyde. However, this potential has not been evaluated in the presence of S9. On the other hand, aspartame did not induce UDS in metabolically-competent rat hepatocytes at concentrations up to 10 mM. Since formaldehyde did induce UDS in Syrian hamster embryo cells (Hamaguchi and Tsutsui, 2000) , which have considerable metabolic capability, this would suggest that the levels of formaldehyde formed from hydrolysis of aspartame are negligible and not genotoxic.
Although some in vitro studies did not comply with current guidelines, the available data indicate that aspartame does not induce gene mutations in bacteria and does not induce primary DNA damage in mammalian cells.
In vivo studies in somatic cells

Micronucleus (MN) tests in bone marrow or blood
The in vivo MN studies are summarised in Table 2 . Whilst the acute bone marrow MN test in rats conducted by NTP (2005) was clearly negative, a positive trend was found for MNNCE in peripheral blood of female p53 haploinsufficient mice after 9 months dosing, but not in male mice or in 2 other genetically modified strains of mice. The MNNCE frequency in this group was >2Â that in the negative control group, however it was similar to MNNCE Small but statistically significant increases in % tail DNA (2.2-fold) and tail length (>10-fold) in top dose group Bandyopadhyay et al. (2008) frequencies in all male groups, and may only have achieved statistical significance because the vehicle control MNNCE frequency in females was slightly low. Importantly, there are no historical MNNCE data for these strains. The finding of a significant increase in only 1 group of females may be due to chance, and there is no obvious reason why female mice of the p53 haploinsufficient strain should respond to a genotoxic insult when none of the other genders or strains showed any response. Magnuson et al. (2007) discussed the cleavage of aspartame in the gastrointestinal tract, and concluded that aspartame itself does not enter the systemic circulation after oral dosing. However, tissues such as the bone marrow would be exposed to the 3 cleavage products, namely aspartic acid, phenylalanine and methanol, and also to the hydrolysis and degradation product diketopiperazine, after dosing via the oral route. The weight of evidence from these NTP (2005) studies therefore indicates that the cleavage products of aspartame do not induce MN in peripheral blood erythrocytes after both short and extended dosing periods. The bone marrow and blood MN study of Kamath et al. (2010) is summarised in Table 2 . It is interesting to note that slides were stained with May-Grünwald-Giemsa, which is not a DNA-specific stain (acridine orange is more commonly used) and may lead to artefacts (see Hayashi et al., 2000) , although it is acceptable according to OECD (2014a). Bone marrow toxicity was supposedly determined by the PCE:NCE ratio, but these data were not reported; the authors merely stated that the PCE:NCE ratio changed. The extent of bone marrow toxicity in the treated animals cannot therefore be determined, and, when dose levels are compared with those tolerated in other studies, 3 of the 4 the dose levels used here may have been cytotoxic. The pattern of MN results obtained is unusual and difficult to explain. MN induced in bone marrow will not appear in the blood until many hours later, and yet the MN responses were higher at 24 h in blood than in bone marrow. The relevance of these increased MN frequencies is therefore difficult to judge. We agree with EFSA (2013) , that the methods implemented were not sufficiently robust to support the results reported, and that no conclusions could be drawn.
Chromosomal aberrations (CA) in bone marrow
Several bone marrow CA studies have been reported and are summarised in Table 2 . In the studies of Bowles (1970) and Durnev et al. (1995) aspartame did not induce any statistically significant increases in the frequencies of CA. The study of Mukhopadhyay et al. (2000) on a mixture of aspartame and acesulfame K also gave negative results, but the single sampling time was earlier than recommended. These studies do lack some detail and do not follow recommended study designs, so the negative results should be viewed with caution. Although blood samples were not taken for toxicokinetic analysis, systemic exposure to the cleavage products of aspartame would have been achieved, as discussed above.
By contrast, Kamath et al. (2010) reported significant induction of CA in mouse bone marrow. The study was run alongside (or in the same animals) as the MN study discussed above, and is summarised in Table 2 . The positive results showed both time-and dose-related trends, which is most unusual since well-known potent genotoxins rarely produce both dose-and time-related increases in CA. When significant CA are induced at an early sampling time, those cells usually die before later sampling times are reached. Also, no mitotic index data were given, and so the extent of toxicity in the bone marrow is not known. Whilst the results are striking, they are difficult to evaluate. Hence, we agree with EFSA (2013) , that the methods implemented were not sufficiently robust to support the results reported, and that no conclusions could be drawn.
AlSuhaibani (2010) also reported statistically significant increases in mouse bone marrow CA (summarised in Table 2 ). However, the actual frequencies in the top 2 dose groups (0.4 and 0.5% cells with CA excluding gaps) are within the normal control ranges found in other studies, and since no historical control data were provided, it is not known whether such increases are biologically significant. We agree with the comments of EFSA (2013), that the methods implemented were not sufficiently robust to support the results reported, and that no conclusions could be drawn from the study. Reno and Bowles (1972) tested the hydrolysis and degradation product of aspartame, diketopiperazine, for induction of chromosomal aberrations (CA) in bone marrow of rats. Although the study was conducted at a contract research laboratory, it was done before GLPs were mandatory. Diketopiperazine was administered orally at 250, 500, 1000 and 2000 mg/kg/day for 5 days to groups of 10 male rats. The doses on each day were divided equally into three. Although repeated dosing is not usually used for the bone marrow CA test, it is acceptable when justified e.g. where daily doses are as high as in an acute study or where there may be accumulation of test chemical in tissues. Since the limit dose of 2000 mg/kg was tolerated daily for 5 days this schedule is considered acceptable. Sampling 1 day after a repeat dose schedule is acceptable. Slight weight losses (around 3% compared to control) were observed in the top dose group. A negative control group received the vehicle, 1% Tween 80 in distilled water, and a positive control group received a single intraperitoneal dose of 0.5 mg/kg triethylenemelamine on day 5. Animals were sacrificed 24 h after the last (or only) dose, having been given Colcemid 5 h previously to arrest dividing cells in metaphase. Bone marrow cells were collected from both femurs, swollen in hypotonic potassium chloride, smears made, fixed and stained with Giemsa. Fifty metaphase cells per rat (i.e. 500 per group) were scored for CA. The number of cells/animal was lower than currently recommended but the increased group size probably allowed acceptable statistical power and sensitivity to be achieved. Frequencies of cells with CA were normal in control animals and were significantly increased by treatment with the positive control. The group treated with 250 mg/kg diketopiperazine exhibited CA frequencies that were similar to controls. The groups treated with 500, 1000 or 2000 mg/kg diketopiperazine all exhibited slightly higher CA frequencies, but these were less than 2Â control levels and all fell within normal ranges. They were not statistically different from controls and the slight increases are not considered to be biologically significant. No blood samples were taken to investigate systemic exposure to diketopiperazine. However, diketopiperazines are considered to have a structure that ensures active intestinal absorption (Cornacchia et al., 2012) . Although the study was not conducted to GLP, and an unusual (repeat dose) study design was used, the study is reasonably robust and the negative results with diketopiperazine merit consideration.
DNA damage assays
The alkaline comet assay of Sasaki et al. (2002) in multiple mouse tissues is summarised in Table 2 . Although suspensions of nuclei were investigated, rather than whole cells, and tail length rather than tail intensity was measured, these approaches are acceptable under OECD guideline 489 (OECD, 2014b) . No direct measures of systemic exposure were included, but, as discussed above, systemic exposure to the cleavage products of aspartame would have occurred following oral dosing. In any case, stomach and colon would have been directly and heavily exposed to aspartame, and to the cleavage products formed there, in this study. Although no increases in DNA migration were seen in any of the 8 tissues sampled, only 50 cells/organ/animal were scored whereas OECD (2014b) recommends 150 cells. Thus, the negative results have to be viewed with some caution.
The alkaline comet assay of Bandyopadhyay et al. (2008) is summarised in Table 2 . Although the dose levels of aspartame were much lower than in other studies, the sampling time of 18 h was much later than recommended (2e6 h), and, again, only 50 cells/ animal were scored for comets in bone marrow cells, a significant increase in DNA migration was seen in the top dose group (35 mg/ kg), chosen as being similar to the acceptable daily intake for humans, namely 40 mg/kg established by the Joint FAO/WHO Expert Committee on Food Additives (JECFA, 1981) . However, the control tail length was short and probably enhanced the statistical significance. No historical control values were reported, and the absolute increases in % tail DNA and tail length were small, so could represent normal background "noise". We agree with the comments of EFSA (2013), that the methods used were not sufficiently robust to support the results, and that no conclusions could be drawn.
Other in vivo studies
Three different host-mediated assays have been performed, one on aspartame in the mouse (Bost, 1974) , and 2 studies with the conversion product diketopiperazine, one in mice (Bost and Stolt, 1974) and the other in rats (Reno and Good, 1972) . In the host mediated assay, animals treated with a test chemical are injected intraperitoneally with one or more Ames strains (in these cases S. typhimurium G-46), then a few hours later the bacteria are recovered from the peritoneal cavity, the bacteria are counted and the frequency of histidine revertants determined. A mutant frequency is calculated. This method allows for the test chemical to be metabolised by the tissues of a normal animal, and for the test chemical or any reactive metabolites to interact with the bacteria in situ to produce reverse mutations. This method is no longer used in regulatory testing as other approaches to the study of induction of gene mutations in vivo (e.g. in transgenic mice) are available. The 3 studies and their outcomes can be summarised as follows. Aspartame in mice:
Groups of 10 male Swiss mice were dosed orally by gavage with aspartame at 1, 2, 4 and 8 g/kg/day for 5 days. The daily doses were divided equally into 3 aliquots given approximately 2 h apart. Vehicle control and positive control (methylazoxymethanol) groups of 10 mice were also included. Body weights and food consumption were not affected by dosing with aspartame. Three animals died during the study, probably from dosing errors (lung doses and oesophageal rupture). Thirty minutes after the final dose, aliquots of nutrient broth cultures of bacteria were injected into the peritoneum. Animals were sacrificed 3 h later and bacteria recovered. Viable counts were determined by plating on nutrient agar, and mutant counts were determined by plating on Spizizen's minimal agar. Based on the counts of bacteria recovered from the peritoneal cavity there was no evidence that aspartame inhibited the replication of the bacteria in situ.
There are no reference data against which to compare mutant frequencies in control animals. However, mutant frequencies were significantly increased (30-fold) in the positive control group. There were no increases in mutant frequency in any of the aspartame-treated groups.
Diketopiperazine in mice:
Groups of 10 male Swiss mice were dosed by gavage with diketopiperazine at 1, 2, 4 and 8 g/kg/day for 5 days. The daily doses were divided equally into 3 aliquots given approximately 2 h apart. Vehicle control and positive control (methylazoxymethanol) groups of 10 mice were also included. Deaths that could be compound-related occurred in the top 2 dose groups (4 and 8 g/kg/day), reducing survival to 80 and 30% respectively. Terminal body weights of and food consumption by surviving animals were not affected by dosing with diketopiperazine. Thirty minutes after the final dose, aliquots of nutrient broth cultures of bacteria were injected into the peritoneum. Animals were sacrificed 3 h later and bacteria recovered. Viable counts were determined by plating on nutrient agar, and mutant counts were determined by plating on Spizizen's minimal agar. Based on the counts of bacteria recovered from the peritoneal cavity there was no evidence that diketopiperazine inhibited the replication of the bacteria in situ.
There are no reference data against which to compare mutant frequencies in control animals. However, mutant frequencies were significantly increased (4-fold) in the positive control group. There were no increases in mutant frequency in any of the diketopiperazine-treated groups.
Diketopiperazine in rats:
Groups of 10 male rats were dosed by gavage with diketopiperazine at 250, 500, 1000 and 2000 mg/kg/day for 5 days. The daily doses were divided equally into 3 aliquots given approximately 2 h apart. Vehicle control and positive control (dimethylnitrosamine) groups of 10 rats were also included, although the positive control was only administered once on the final day. Deaths that could be compound-related occurred in the top dose group reducing survival to 80%. Terminal body weights of and food consumption by surviving animals were reduced following dosing with diketopiperazine. Thirty minutes after the final dose, aliquots of nutrient broth cultures of bacteria were injected into the peritoneum. Animals were sacrificed 3 h later and bacteria recovered. Viable counts were determined by plating on tryptone agar, and mutant counts were determined by plating on Spizizen's minimal agar. Based on the counts of bacteria recovered from the peritoneal cavity there was no evidence that diketopiperazine inhibited the replication of the bacteria in situ.
There are no reference data against which to compare mutant frequencies in control animals. However, mutant frequencies were significantly increased (18-fold) in the positive control group. There were no increases in mutant frequency in any of the diketopiperazine-treated groups.
Thus, high doses of aspartame or diketopiperazine did not induce mutations in S. typhimurium G-46 when exposed in vivo in host mediated assays in mice and rats.
AlSuhaibani (2010) also measured sister chromatid exchanges (SCE) in the in vivo bone marrow CA study in mice described earlier (see Table 2 ). Slight increases in SCE/cell were reported but were not statistically significant. This endpoint is no longer included in regulatory testing as the biological relevance of any findings is unclear.
Summary of in vivo somatic cell data
In all of the above in vivo studies, administration by the oral route was used. Following oral dosing, the GI tract (site of contact) would have been exposed to aspartame, but internal organs would have been exposed to aspartic acid, phenylalanine and methanol, and also to the hydrolysis and degradation product diketopiperazine, rather than aspartame per se. Several of the in vivo MN and CA studies, and one of the comet assays, produced positive results, but are difficult to evaluate and the conclusions are questionable. The positive MN finding by NTP (2005) in only female mice of 1 strain when male mice and other strains were negative suggests this does not represent inherent genotoxic activity. Other studies, including a comet assay examining site-of-contact tissues, produced negative results, and are considered more robust. CA studies in bone marrow of rats dosed daily for 5 days with high doses of diketopiperazine also gave negative results. By weight of evidence, the clastogenic and DNA-damaging potential of aspartame seen in vitro has not been confirmed in vivo. The host-mediated and SCE assays with aspartame and diketopiperazine do not really contribute to the assessment, but tend to confirm the negative gene mutation potential seen in vitro. Thus, sufficient data on relevant endpoints in vivo have been obtained to be able to evaluate the genotoxic potential seen in vitro and, in the most reliable studies, have given negative results. It is therefore reasonable to conclude that aspartame is not genotoxic in somatic cells at high doses in vivo.
In vivo studies on germ cells
The spermatogonial CA test of Bowles (1970) is summarised in Table 3 . Dosing was over 5 days, and although repeated dosing is not recommended for the spermatogonial CA test (Adler et al., 1994) , it is considered acceptable by OECD if justified, e.g. where daily doses are as high as in an acute study or where there may be accumulation of test chemical in tissues. The top daily dose was 1600 mg/kg which is as high, or higher, than used in some of the acute studies on somatic cells. The number of cells scored/animal was lower than currently recommended but the increased group size ensured that the numbers of cells scored/group achieved acceptable statistical power and sensitivity. The positive control, triethylenemelamine, induced a significant increase in bone marrow cells with CA, but it appears that spermatogonial cells of rats treated with triethylenemelamine were not scored. The second positive control was cyclohexylamine, a sweetener that had previously been reported to be genotoxic in both somatic and germ cells, and was expected to induce CA in spermatogonia, however it was not confirmed to be clastogenic in this study. No blood samples were taken for analysis, but systemic exposure to the cleavage products of aspartame (aspartic acid, phenylalanine and methanol) would have been achieved as discussed earlier and in Magnuson et al. (2007) . Thus, although aspartame did not induce any statistically significant increases in the frequencies of CA in spermatogonia, the lack of relevant positive control responses indicates the results should be viewed with caution.
The dominant lethal test of Schroeder et al. (1973) with aspartame is summarised in Table 3 . Although no guidelines were available at the time of the study, recommendations that were subsequently published (Adler et al., 1994) were generally followed, although larger numbers of males would have provided greater sensitivity. The study was concluded negative. Schroeder et al. (1973) also tested a conversion product of aspartame, diketopiperazine, for induction of dominant lethal effects in rats using the same protocol as for aspartame. Again, diketopiperazine did not induce any dominant lethal effects.
A study of abnormal sperm by Kamath et al. (2010) was performed alongside the MN and CA studies discussed earlier, and is summarised in Table 3 . Whilst a dose dependent increase in % abnormal sperm was reported, and frequencies were significantly different from vehicle controls at all doses, the earlier comments of EFSA (2013) that the methods implemented were not sufficiently robust to support the results reported, would again indicate that no conclusions could be drawn.
Summary of germ cell data
Genotoxicity data in germ cells are not usually required unless a substance has induced genotoxic effects in somatic cells in vivo. Aspartame did not induce chromosomal aberrations in spermatogonia of rats, but the study may not be considered robust due to the lack of effective positive controls. Both aspartame and diketopiperazine failed to induce dominant lethal mutations in rats in studies that were reasonably robust but did not meet current standards. Although increased frequencies of abnormal sperm were observed, the dose levels may have been cytotoxic, and the relevance of the result is unclear.
Conclusions
The in vitro and in vivo genotoxicity data available on aspartame have been reviewed. The endpoints investigated in vitro and in vivo comply with the latest testing recommendations of EFSA (2011b) and are therefore considered sufficient for a thorough evaluation. There is no evidence of induction of gene mutations in a series of bacterial mutation tests. Whilst there is some evidence of induction of chromosomal damage in vitro, this is probably a secondary effect of cytotoxicity and not due to primary DNA damage. Furthermore, the weight of evidence from the most robust in vivo bone marrow micronucleus, chromosomal aberration and comet studies indicates absence of genotoxic activity for somatic tissues in animals. The results of germ cell assays are difficult to evaluate considering A dose dependent increase in % abnormal sperm was reported, and frequencies were significantly different from vehicle controls at all doses. Kamath et al. (2010) the limited data available and deviations from standard protocols. The data available therefore support the conclusions of EFSA (2013) and of Magnuson et al. (2007) that aspartame does not show any genotoxic potential.
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